Novel Therapeutic Approaches to Alzheimer’s Disease: A Focus on Immunotherapy

The content for this activity is based on the satellite symposium, "Novel Therapeutics Approaches to Alzheimer’s Disease: A Focus on Immunotherapy" that was presented at AAIC 2015. This CME activity will address novel approaches to disease-modifying treatment of Alzheimer's Disease (AD), with a specific focus on potential role of immunotherapies. The current antibody landscape will be presented, as will the challenges of studying immunotherapy in early disease and an update on PET imaging of both amyloid and tau.

Target Audience

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with AD.

Learning Objectives 

Upon completion of this activity, participants will be better able to:

  1. Discuss the importance of early detection and managementof AD 
  2. Identify immunotherapies in development for the treatment of AD
  3. Analyze the use of biomarkers to identify patients with early-stage AD 

Faculty

 

Paul S. Aisen, MD (Program Chair)
Director, Alzheimer’s Therapeutic Research Institute
University of Southern California
San Diego, California

Stephen Salloway, MD, MS
Director of Neurology and of the Memory and Aging Program
Butler Hospital
Professor of Neurology and Psychiatry
The Warren Alpert Medical School of Brown University
Providence, Rhode Island


Keith Johnson, MD
Director, Molecular Neuroimaging
Massachusetts General Hospital
Professor of Radiology
Harvard Medical School
Boston, Massachusetts

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Relationship Identified With:

Paul S. Aisen, MD

Consultant/Advisor: Biogen, Inc
Grant/Research Support: Lilly

Stephen Salloway, MD, MS

Consultant/Advisor: Biogen, Inc, Genentech, Lilly, Merck, Roche

Grant/Research Support: Avid, Biogen, Inc, Functional Neuromodulation, Genentech, Lilly, Merck, Roche

Keith Johnson, MD 

Consultant/Advisor:Avid/Lilly, Janssen, Novartis, Piramal, Roche (Spouse: Consultant/Advisor: Avid/Lilly)

Grant/Research Support: Avid/Lilly, Biogen Idec, Janssen

The Planners, Managers, and ReviewersSandy Breslow; Bernard Abrams, MD; Alison Kemp; and Lyerka Miller, PhD; hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any com­mercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Biogen, Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. 

 

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Course Open Date: December 28, 2015 | Course Expiration Date: December 27, 2016

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education; Miller Medical Communications, LLC; and Biogen do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of The Elsevier Office of Continuing Medical Education; Miller Medical Communications, LLC; or Biogen. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Course opens: 
12/28/2015
Course expires: 
12/27/2018
Rating: 
5

Available Credit

Accreditation Period

Course opens: 
12/28/2015
Course expires: 
12/27/2018
Please login or register to take this course.